Valneva SE (VALN) News
Filter VALN News Items
VALN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VALN News Highlights
- VALN's 30 day story count now stands at 3.
- Over the past 15 days, the trend for VALN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about VALN are SE.
Latest VALN News From Around the Web
Below are the latest news stories about VALNEVA SE that investors may wish to consider to help them evaluate VALN as an investment opportunity.
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of DirectorsAnne-Marie Graffin is appointed as Chair of the Board of Directors Saint-Herblain (France), December 20, 2023 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its shareholders approved the resolutions recommended by the Management Board at its Extraordinary General Meeting (EGM) held on December 20, 2023. These included the immediate transition from the Company’s two-tier governance model to a one-tier model led by a Board of Directors. During a |
VALNEVA Declaration of shares and voting rights - November 30, 2023VALNEVA Declaration of shares and voting rights November 30, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: December 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this chan |
Pfizer, after delay, completes enrollment in Lyme vaccine trialThe announcement ends a lengthy setback that began when the company and partner Valneva accused a clinical trial site operator of study misconduct. |
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025Pfizer aims to submit regulatory filings in the U.S. and Europe in 2026 New York, NY, and Saint-Herblain (France), December 4, 2023 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that they have |
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Primary endpoint met with 97% seroresponse rate 24 months after a single vaccinationAntibody levels remained high and well above the seroresponse threshold, further supporting the anticipated long-term durability of the immune response No safety concerns identified in long-term follow up Saint-Herblain (France), December 4, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty |
EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated AssessmentSaint-Herblain (France), November 27, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has performed a technical validation of the Marketing Authorization Application (MAA) for Valneva’s single-shot chikungunya vaccine candidate VLA1553 and has determined that all essential regulatory elements required for scientific assessment were included in the application. The MAA was granted accelerated assessment1 |
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of DirectorsSaint-Herblain (France), November 15, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the availability of documentation for its Extraordinary General Meeting (“General Meeting” or “EGM”) which will be held on December 20, 2023 at 2:00 p.m. CET at the Radisson Blu Hotel, 6 place Aristide Briand, 44000 Nantes, France. As announced in June 20231, during this EGM, shareholders will notably vote on the Supervisory Board’s recommendation to transitio |
Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine CandidateSaint-Herblain (France), November 13, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive pivotal Phase 3 immunogenicity data in adolescents for its single-dose chikungunya virus (CHIKV) vaccine candidate VLA1553. These results complement the initial Phase 3 safety data the Company reported for the trial in August 20231. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union’s Horizon 2020 |
Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Call TranscriptValneva SE (NASDAQ:VALN) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good day and thank you for standing by. Welcome to the Valneva 9 Months 2023 Financial Results Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Joshua Drumm, VP, Investor Relations. Please go ahead. Joshua Drumm: […] |
Valneva’s chikungunya vaccine approved by FDAThe preventive shot is the first to receive regulatory approval for the mosquito-borne illness, which is growing in prevalence worldwide. |